These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 16142848)

  • 1. Alfacalcidol versus plain vitamin D in inflammation induced bone loss.
    Scharla SH; Schacht E; Lempert UG
    J Rheumatol Suppl; 2005 Sep; 76():26-32. PubMed ID: 16142848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
    Ringe JD; Faber H; Fahramand P; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY; Lecart MP; Richy F
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.
    Schacht E; Richy F; Reginster JY
    J Musculoskelet Neuronal Interact; 2005; 5(3):273-84. PubMed ID: 16172518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The D-hormone analog alfacalcidol: the pioneer beyond the horizon of osteoporosis treatment.
    Orimo H; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():4-10. PubMed ID: 16142845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Osteoporosis in rheumatoid arthritis--significance of alfacalcidol in prevention and therapy].
    Schacht E
    Z Rheumatol; 2000; 59 Suppl 1():10-20. PubMed ID: 10769429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction. D-hormones alfacalcidol and calcitriol for prevention and treatment of glucocorticoid/inflammation-induced osteoporosis.
    Sambrook PN; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():1-3. PubMed ID: 16142844
    [No Abstract]   [Full Text] [Related]  

  • 8. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.
    Richy F; Schacht E; Bruyere O; Ethgen O; Gourlay M; Reginster JY
    Calcif Tissue Int; 2005 Mar; 76(3):176-86. PubMed ID: 15692726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs.
    Schacht E; Dukas L; Richy F
    J Musculoskelet Neuronal Interact; 2007; 7(2):174-84. PubMed ID: 17627088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential of alfacalcidol for reducing increased risk of falls and fractures.
    Ringe JD; Schacht E
    Rheumatol Int; 2009 Aug; 29(10):1177-85. PubMed ID: 19159932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.
    Ringe JD; Schacht E
    Rheumatol Int; 2007 Dec; 28(2):103-11. PubMed ID: 17668216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.
    Ringe JD; Dorst A; Faber H; Schacht E; Rahlfs VW
    Rheumatol Int; 2004 Mar; 24(2):63-70. PubMed ID: 14513268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eldecalcitol: newly developed active vitamin D(3) analog for the treatment of osteoporosis.
    Hagino H
    Expert Opin Pharmacother; 2013 Apr; 14(6):817-25. PubMed ID: 23477453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low creatinine clearance, glucocorticoid treatment, rheumatoid arthritis--different etiologies for low D-hormone syndrome and its associated increased risk for falls.
    Dukas LC; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():44-6. PubMed ID: 16142851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relative value of plain vitamin D and of biologically active vitamin D in the prevention and treatment of osteoporosis].
    Scharla S
    Z Rheumatol; 2006 Sep; 65(5):391-4, 396-9. PubMed ID: 16944081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
    De Nijs RN
    Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for active vitamin D and analogs in the treatment of osteoporosis.
    Nishii Y
    J Cell Biochem; 2003 Feb; 88(2):381-6. PubMed ID: 12520540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.
    Ringe JD; Farahmand P; Schacht E
    Rheumatol Int; 2013 Mar; 33(3):637-43. PubMed ID: 22527138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol.
    Schacht E
    Calcif Tissue Int; 1999 Oct; 65(4):317-27. PubMed ID: 10485985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to prevent glucocorticoid-induced osteoporosis.
    Dore RK
    Cleve Clin J Med; 2010 Aug; 77(8):529-36. PubMed ID: 20682515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.